| Literature DB >> 6490201 |
G S Berkowitz, J L Kelsey, V A LiVolsi, M J Merino, T R Holford, N G Hildreth, S Ort, T Z O'Connor, C White.
Abstract
In a hospital-based case-control study of 590 women with biopsy-proven fibrocystic breast disease and 1,018 control women with other surgical conditions, no linear relationship was evident between the use of oral contraceptives or of estrogen replacement therapy and the degree of epithelial atypia of the fibrocystic lesions. Case-control and intracase comparisons suggested that oral contraceptive use might be associated with an increased occurrence of sclerosing adenosis among the premenopausal women and of gross cysts among the postmenopausal women. Estrogen replacement therapy, which was positively associated with fibrocystic breast disease as a whole among the post-menopausal women, was most frequently used among the cases whose biopsy specimens exhibited gross cysts, papillomatosis or papillary hyperplasia.Entities:
Keywords: Age Factors; Biology; Contraception; Contraceptive Agents, Female--side effects; Contraceptive Agents--side effects; Contraceptive Methods--side effects; Control Groups; Data Collection; Diseases; Endocrine System; Estrogens--side effects; Family Planning; Hormones; Mammary Gland Effects; Oral Contraceptives--side effects; Physiology; Population At Risk; Population Characteristics; Reproductive Control Agents; Research Methodology
Mesh:
Substances:
Year: 1984 PMID: 6490201 DOI: 10.1002/ijc.2910340403
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396